Hello everyone,

a good friend of mine, a medical student, expressed his surprise about the fact that there might be some very promising substances for treating AD, especially Cu(II)gtsm, still, no company or research institute evaluates them in the course of a clinical trial.

Now, I am no physicist myself, but, being very interested in human biology and intrigued by his remarks, I read about that ligand and wonder why it has not been tested in clinical trials to date.

Cu(II)gtsm, a btsc-ligand, is known since the 60s. The potential therapeutic benefit of this ligand for AD, again, has been tested as early as 2009 (10 years ago):

"CuII(gtsm) also decreased the abundance of Aβ trimers and phosphorylated tau, and restored performance of AD mice in the Y-maze test to levels expected for cognitively normal animals. Improvement in the Y-maze correlated directly with decreased Aβ trimer levels. (Crouch et al., 2009)."

Source: Article Alzheimer's disease & metals: Therapeutic opportunities

This is especially striking, as Cu(II)atsm, another btsc-ligand, is currently in a CT for ALS, holding the promise of being the first substance, to massively slow down the progression of this devastating neurological disease or even dose- and patient-depently halt it completly, with remarkable interim results, despite the small sample. (https://tandfonline.com/doi/pdf/10.1080/21678421.2017.1374609?needAccess=true). Therefore the potential of btsc-ligands has been recognized.

Out of curiosity: Why does it take so long to test a substance with such astonishing pre-clinical results? (The article even names some more.)

Kind regards,

Christian